Centre for Research into Cancer Prevention and Screening, University of Dundee, UK.
BMC Public Health. 2011 Mar 25;11:184. doi: 10.1186/1471-2458-11-184.
Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second highest cause of cancer death in the UK. Most cases occur in people over 50 years and CRC often co-exists with other lifestyle related disorders including obesity, type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). These diseases share risk factors related to the metabolic syndrome including large body size, abnormal lipids and markers of insulin resistance indicating common aetiological pathways.
METHODS/DESIGN: This 3 year study will be a two-arm, multicentre, randomised controlled trial comparing the BeWEL lifestyle (diet, physical activity and behaviour change) programme against usual care. The pre-trial development will take 6 months and participants will be recruited over a 12 month period and undertake the intervention and follow up for 12 months (total 24 months recruitment and intervention implementation) with a further 6 months for data collection, analysis and interpretation.Four hundred and fifty two participants who have had a colorectal adenoma detected and removed (through the national colorectal screening programme) will provide 80% power to detect a weight loss of 7% over 12 months.Primary outcomes are changes in body weight and waist circumference. Secondary outcomes will include cardiovascular risk factors, psycho-social measures and intervention costs.
The results from this study will enhance the evidence base for lifestyle change in patients at higher risk of chronic disease including obesity related cancers.International Standard Randomised Controlled Trials No: ISRCTN53033856.
结直肠癌(CRC)是英国第三大常见癌症,也是癌症死亡的第二大主要原因。大多数病例发生在 50 岁以上的人群中,CRC 常与其他与生活方式相关的疾病并存,包括肥胖、2 型糖尿病(T2DM)和心血管疾病(CVD)。这些疾病具有与代谢综合征相关的共同危险因素,包括身体过大、脂质异常和胰岛素抵抗标志物,表明存在共同的病因途径。
方法/设计:这项为期 3 年的研究将是一项为期 2 年的双臂、多中心、随机对照试验,比较 BeWEL 生活方式(饮食、身体活动和行为改变)方案与常规护理。预试验开发将需要 6 个月的时间,参与者将在 12 个月内招募,并进行 12 个月的干预和随访(总招募和干预实施时间为 24 个月),随后有 6 个月的时间用于数据收集、分析和解释。452 名已通过全国结直肠筛查计划检测并切除结直肠腺瘤的参与者将提供 80%的效力来检测 12 个月内体重减轻 7%。主要结局是体重和腰围的变化。次要结局将包括心血管风险因素、心理社会措施和干预成本。
这项研究的结果将增强生活方式改变在患有肥胖相关癌症等慢性病风险较高的患者中的循证基础。国际标准随机对照试验编号:ISRCTN53033856。